What you can do, Cares Events, Updates and More With the coronavirus (COVID-19) situation evolving, CureDuchenne is closely monitoring the latest developments using the World Health Organization, Centers for Disease […]
In this webinar, Beth Belluscio, MD, PhD, Pfizer Global Clinical Lead for Rare Neurological Disorders, discusses the Phase 3 study of PF-06939926, a gene therapy for Duchenne muscular dystrophy. Dr. Belluscio answers questions […]
NEWPORT BEACH, Calif., (March 10, 2020) – CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will co-host a free webinar with Pfizer to discuss their […]
NEWPORT BEACH, Calif., (March 10, 2020) – CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will co-host a free webinar with Pfizer to discuss their […]
NEWPORT BEACH, Calif., (March 4, 2020) – Hundreds gathered at the Monarch Beach Resort on Saturday, February 29 to enjoy the best of Napa Valley wineries and help find a cure […]
3/13/2020: UPDATED ANNOUNCEMENT AVAILABLE HERE » We never want to put anyone from the Duchenne community at risk, and with the statements from the CDC regarding travel risks, especially for persons […]
CureDuchenne congratulates Pfizer on their progress to a Phase III clinical trial for #PF-06939926, its AAV9 mini-dystrophin gene therapy for Duchenne muscular dystrophy. We’re grateful to Pfizer for their dedication […]
The Congressionally Directed Medical Research Programs’ (CDMRP), Duchenne Muscular Dystrophy Research Program (DMDRP) consumer advocates Tiffany Cook and Clint M. Porter recently participated in the evaluation of research applications submitted […]
CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will contribute patient-level clinical data to the Vivli platform, making it available to other researchers around […]
